Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors

PURPOSE: An association between mutational burden and response to immune checkpoint therapy has been documented in several cancer types. The potential for such a mutational burden threshold to predict response to immune checkpoint therapy was evaluated in several clinical datasets, where mutational...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Panda, Anshuman, Betigeri, Anil, Subramanian, Kalyanasundaram, Ross, Jeffrey S., Pavlick, Dean C., Ali, Siraj, Markowski, Paul, Silk, Ann, Kaufman, Howard L., Lattime, Edmund, Mehnert, Janice M., Sullivan, Ryan, Lovly, Christine M., Sosman, Jeffrey, Johnson, Douglas B., Bhanot, Gyan, Ganesan, Shridar
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6016848/
https://ncbi.nlm.nih.gov/pubmed/29951597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados